Head and Neck Squamous Cell Carcinoma Market Report 2025

This Head and Neck Squamous Cell Carcinoma market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The head and neck squamous cell carcinoma market size has grown strongly in recent years. It will grow from $1.81 billion in 2024 to $1.98 billion in 2025 at a compound annual growth rate (CAGR) of 9.4%. The growth during the historic period can be attributed to increased awareness and screening, the growth of combination therapies, the development of healthcare infrastructure, rising healthcare spending, and the increasing incidence of head and neck squamous cell carcinoma.

The head and neck squamous cell carcinoma market size is expected to see strong growth in the next few years. It will grow to $2.81 billion in 2029 at a compound annual growth rate (CAGR) of 9.2%. The expected growth in the forecast period is driven by factors such as rising tobacco consumption, a growing geriatric population, favorable government policies, an increasing incidence of cancer, and higher alcohol consumption. Key trends during this period include the adoption of targeted therapies, increased investment in research, the integration of immunotherapy, technological advancements, and improvements in drug formulation.

The growing consumption of tobacco and alcohol is anticipated to drive the expansion of the head and neck squamous cell carcinoma market. This rise is influenced by factors such as cultural norms, social pressures, stress, marketing, and the easy availability of these substances. The consumption of tobacco and alcohol contributes to an increased risk of head and neck squamous cell carcinoma (HNSCC) by causing chronic irritation and damage to the mucosal lining, triggering genetic mutations, and weakening immune responses, all of which promote cancer development in the head and neck area. For example, in September 2024, the Centers for Disease Control and Prevention (CDC) reported that tobacco use remains the leading cause of preventable disease and death in the U.S. In 2022, approximately 49.2 million adults, or 19.8% of the population, used tobacco products. Additionally, data released by the UK’s National Health Service in June 2024 indicated that 81% of adults consumed alcohol in the previous year, with 84% of men and 78% of women reporting alcohol use during this period. As such, the increasing use of tobacco and alcohol is contributing to the growth of the head and neck squamous cell carcinoma market.

To foster innovation in cancer treatments, leading companies in the head and neck squamous cell carcinoma field are forming strategic partnerships. These collaborations allow companies to pool resources and expertise, speeding up research and development while boosting innovation. By joining forces, these partnerships also facilitate faster commercialization, helping companies reach broader markets and access new patient groups. For example, in October 2024, Exelixis Inc., a U.S.-based biotech firm, teamed up with Merck & Co. Inc., a U.S.-based pharmaceutical company, to further cancer treatments. This collaboration aims to explore the combination of zanzalintinib with KEYTRUDA and WELIREG, targeting enhanced outcomes for patients with HNSCC and renal cell carcinoma (RCC).

In March 2023, Flamingo Therapeutics NV, a Belgian biotechnology firm, merged with Dynacure SAS in a deal with undisclosed terms. This merger allows the two companies to combine their expertise in RNA-targeting and clinical drug development, creating a prominent oncology entity focused on advancing cutting-edge therapies. This includes Flamingo’s danvatirsen program, currently undergoing Phase II trials for head and neck cancer, and the FTX-001 program targeting MALAT-1 in solid tumors. Dynacure SAS is a Belgium-based biotech company specializing in developing therapies for patients with rare and severe orphan diseases.

Major players in the head and neck squamous cell carcinoma market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Bayer AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GSK plc, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Rakuten Medical Inc., Exelixis Inc., Akeso Inc., Fortress Biotech Inc., Hookipa Pharma Inc., MacroGenics Inc., Theriva Biologics Inc., Turnstone Biologics Inc., Nykode Therapeutics AS, Immutep Limited, Tizona Therapeutics Inc., Checkpoint Therapeutics Inc., and Zenith Epigenetics Ltd.

North America was the largest region in the head and neck squamous cell carcinoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in head and neck squamous cell carcinoma report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the head and neck squamous cell carcinoma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Head and neck squamous cell carcinoma (HNSCC) is a malignant tumor that arises in the squamous epithelium of the upper aerodigestive tract, affecting areas such as the oral cavity, pharynx, and larynx. It is one of the most common types of head and neck cancer, often associated with risk factors such as tobacco use, alcohol consumption, and infections such as human papillomavirus (HPV).

The main types of head and neck squamous cell carcinoma include salivary gland, oral and oropharyngeal, nasal cavity and paranasal sinuses, nasopharyngeal, laryngeal, and hypopharyngeal cancers. Salivary gland cancers are rare malignancies that develop in the glands producing saliva and are usually treated with surgery, radiation, and targeted therapies. Drug classes used in treatment include epidermal growth factor receptor (EGFR) inhibitors, immune checkpoint inhibitors, and other therapies. These can be administered via intravenous, oral, or other routes. Treatment methods include radiation therapy, chemotherapy, and immunotherapy, with administration across various settings such as hospitals, specialty clinics, and ambulatory surgical centers.

The head and neck squamous cell carcinoma market research report is one of a series of new reports that provides head and neck squamous cell carcinoma market statistics, including the head and neck squamous cell carcinoma industry global market size, regional shares, competitors with the head and neck squamous cell carcinoma market share, detailed head and neck squamous cell carcinoma market segments, market trends, and opportunities, and any further data you may need to thrive in the head and neck squamous cell carcinoma industry. This head and neck squamous cell carcinoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The head and neck squamous cell carcinoma market consists of revenues earned by entities by providing services such as diagnostic services, treatment services, rehabilitation services, and palliative care. The market value includes the value of related goods sold by the service provider or included within the service offering. The head and neck squamous cell carcinoma market also includes sales of therapeutics, regenerative products, targeted therapy treatments, and supportive care products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.